What Percentage of Sessile Polyps Are Cancerous?

Most sessile polyps found during colonoscopy are not cancerous at the time of discovery. The vast majority are benign growths, either hyperplastic polyps with negligible risk or sessile serrated lesions that sit on an early rung of a slow ladder toward cancer. But “sessile polyp” is not one thing, and the cancer risk varies enormously depending on the subtype, size, location, and whether the polyp shows signs of abnormal cell changes called dysplasia. Among sessile serrated lesions specifically, roughly 4% to 15% harbor dysplasia, and a subset of those can progress to invasive cancer over years to decades. The picture gets more complicated once you factor in that sessile shape itself is an independent risk marker for deeper invasion when cancer is present.

Not All Sessile Polyps Are the Same

“Sessile” describes how a polyp sits against the colon wall: flat or slightly raised, without a stalk. That describes a shape, not a diagnosis. A sessile polyp could be a harmless hyperplastic polyp, a sessile serrated lesion with real malignant potential, or a conventional adenoma that happens to grow flat rather than on a stalk. Each of these carries a very different cancer risk, and grouping them under one umbrella is where most confusion begins.

Hyperplastic polyps make up the largest share of sessile polyps found in the colon, and they are overwhelmingly benign. The small ones found in the lower colon almost never progress to cancer. Sessile serrated lesions, on the other hand, look deceptively similar to hyperplastic polyps under the scope but follow a distinct molecular path that can lead to colorectal cancer. Telling these two apart is so difficult that even pathologists disagree. One study found that when pathologists re-examined confirmed hyperplastic polyps using additional tissue sections, about 11% were reclassified as sessile serrated lesions, with even higher reclassification rates for small polyps found in the upper colon.¹ Efforts to standardize diagnostic criteria are ongoing, but there is still no universally accepted gold standard for distinguishing the two.²

Sessile Serrated Lesions and the Road to Cancer

Sessile serrated lesions (SSLs) are the sessile polyps that get the most clinical attention, and for good reason. They are thought to be the starting point for roughly 20% to 30% of all colorectal cancers.³ Some estimates put that figure as high as one third.⁴ These cancers develop through what is called the serrated pathway, which is molecularly distinct from the more familiar adenoma-to-carcinoma sequence that accounts for most other colorectal cancers.

The molecular engine driving the serrated pathway is a mutation called BRAF V600E. This mutation is found in the majority of sessile serrated lesions and in roughly 75% to 90% of the cancers that ultimately arise from them.⁵ Because this mutation is rarely found in conventional adenomas, its presence is one of the clearest signals that a polyp belongs to the serrated family. When BRAF V600E combines with a process that silences tumor-suppressor genes through chemical tagging of DNA, the polyp can progress from a flat, innocuous-looking growth to dysplasia and eventually to invasive cancer.

So how often does that actually happen? A systematic review of U.S. and European studies found that the proportion of SSLs showing dysplasia ranged from about 4% to 43%, with an overall average near 14%. When one statistical outlier was removed, the average dropped to about 10%.⁶ Dysplasia is not the same as cancer, but it represents a waypoint. An SSL with dysplasia is further along the path to malignancy and warrants more aggressive management than one without.

Location and Size Change the Odds Substantially

Two factors dominate the risk profile of any sessile polyp: where it sits in the colon and how big it is. Both matter far more than most patients realize.

Sessile serrated lesions cluster in the right (proximal) colon, which is the harder-to-reach stretch farthest from the rectum. This is also the region where serrated-pathway cancers tend to arise. In a large study following over 233,000 people, those with large serrated polyps in the proximal colon had a 10-year colorectal cancer incidence rate of about 30 per 1,000 persons, compared with roughly 5 per 1,000 for people with no polyps at all. Small proximal serrated polyps carried an intermediate risk, around 15 per 1,000.⁷ For distal (left-sided) serrated polyps, the risk was much lower and closer to the general population baseline.

Size amplifies the risk at every location. Among advanced polyps that had already developed either high-grade dysplasia or early cancer, a study of over 560 patients found that 83% of those in the proximal colon were sessile, compared with 57% in the distal colon. Proximal lesions were nearly four times more likely to be sessile than distal ones.⁸ The pattern is consistent: sessile shape, proximal location, and larger size each independently nudge the risk upward, and together they define the highest-risk category of sessile polyps.

Another important risk multiplier is the presence of conventional adenomas found alongside serrated polyps. In the same large cohort study, people who had both serrated polyps and synchronous adenomas carried a substantially higher cancer risk than those who had serrated polyps alone, with a hazard ratio of about 4 for proximal cases.⁷

When a Sessile Polyp Already Contains Cancer

A small fraction of sessile polyps removed during colonoscopy turn out to already contain invasive cancer, a scenario called a “malignant polyp.” This is where sessile shape becomes especially significant for treatment decisions, because the management of a malignant sessile polyp is fundamentally different from that of a malignant polyp on a stalk.

For a polyp with a stalk, the stalk itself provides a buffer zone. If cancer has not invaded beyond the stalk and the margins are clear, endoscopic removal alone can be curative. Sessile malignant polyps lack that buffer. Clinical guidelines note that a malignant sessile polyp at the earliest stage of wall invasion is generally not considered cured by endoscopic removal alone.⁹ The reasoning is straightforward: without a stalk to act as a safety margin, the cancer has a shorter path to deeper tissue layers and the lymphatic system.

The depth to which cancer has penetrated the submucosal layer is the single most important factor in deciding whether surgery is needed after a sessile polyp is removed. U.S. multi-society guidelines classify invasion less than 1 mm deep as “superficial” and associate it with a very low risk of lymph node spread, in the range of 0% to 4%, provided the polyp is well-differentiated and the margins are clean. Once invasion reaches 1 mm or deeper, the risk of residual disease in the bowel wall or lymph nodes jumps to roughly 10% to 18%, and surgical resection is generally recommended.¹⁰ That same guidance highlights the margin of tissue between the cancer and the resection edge as a key factor: when the margin was at least 1 mm, residual disease rates dropped to 0%, but positive or indeterminate margins carried residual disease rates of 16% to 21%.

In one series of 51 patients who had malignant sessile polyps removed endoscopically, submucosal invasion exceeded 1 mm in over 86% of cases. Despite that high rate, only one patient turned out to have residual malignant disease in the surgical specimen after follow-up surgery.¹¹ That result is encouraging, but the numbers are small, and it illustrates why decisions about surgery after malignant polyp removal are made case by case rather than by blanket rules.

The Detection Problem

Even the most dangerous sessile polyps can only be managed if they are found, and sessile polyps are missed far more often than polyps that grow on stalks. In a study using back-to-back colonoscopies to measure miss rates, flat and sessile polyps were missed about 33% of the time, compared with roughly 8% for polyps with a stalk or semi-stalk. Smaller polyps fared worse: those 5 mm or under were missed about 35% of the time.¹² Because sessile serrated lesions tend to be flat, pale, and covered with a thin mucus cap, they blend into the surrounding tissue in a way that makes them easy to overlook even for experienced endoscopists.

This miss rate has real consequences. The serrated pathway can progress to cancer over a period of years, but when a polyp is missed, the clock keeps ticking until the next screening. Interval cancers, meaning cancers that appear between scheduled screenings, are disproportionately serrated-pathway tumors, likely reflecting missed sessile lesions.

Artificial intelligence is starting to change this. Computer-aided detection systems that overlay real-time alerts during colonoscopy have shown a roughly 78% reduction in the miss rate for sessile serrated lesions.¹³ These systems are trained to flag the subtle surface patterns that distinguish sessile serrated lesions from normal mucosa, compensating for exactly the visual challenge that makes them so hard for human eyes to catch.

What Happens After a Sessile Polyp Is Removed

Removal technique matters. Standard endoscopic mucosal resection (EMR), the most common method for removing large sessile polyps, carries a local recurrence rate of about 15% to 17%. By contrast, endoscopic submucosal dissection (ESD), a more technically demanding procedure that lifts the polyp off in one piece, drops that rate to under 2%.¹⁴ A meta-analysis of randomized trials confirmed that ESD carries significantly lower recurrence rates than EMR, with no significant difference in complication rates between the two techniques.¹⁵ ESD is more widely available in some countries than others, and access can be a practical barrier for patients.

After removal, your long-term cancer risk depends heavily on what was found. A large study tracking patients after polypectomy found that people who had advanced adenomas removed faced a cancer risk roughly four times that of people with no polyps, while those with large serrated polyps had about three times the risk. Patients whose removed polyps were small and non-advanced had no significantly increased risk at all.¹⁶ The risk appears to peak in the first few years after removal: another study found that people with high-risk serrated polyps had over eight times the baseline cancer risk at 3 years post-polypectomy.¹⁷

Surveillance Recommendations After Removal

Surveillance guidelines for sessile serrated polyps differ depending on which medical society you follow, which can be confusing if you are trying to understand your own follow-up schedule. For small sessile serrated polyps without dysplasia, U.S. guidelines generally recommend a follow-up colonoscopy within 5 to 10 years for one to two small polyps, shortening to 3 to 5 years for three to four. European and British guidelines are more conservative, often recommending a return to standard population screening rather than a dedicated surveillance colonoscopy for these low-risk findings.¹⁸

Once a sessile serrated lesion shows dysplasia, or is large (10 mm or more), or appears alongside conventional adenomas, the intervals tighten across all guidelines. Most recommend a follow-up colonoscopy within 3 years for these higher-risk findings. The tighter schedule reflects the elevated cancer risk established in the cohort data described earlier, where large serrated polyps and those with synchronous adenomas carried meaningfully higher long-term cancer rates.

Who Gets Sessile Serrated Lesions

Sessile serrated lesions show a demographic pattern distinct from conventional adenomas. Women are more likely to have them detected, with one large outpatient colonoscopy study finding detection rates of about 16% in women compared with 12% in men. The gap was even wider in patients under 50, where women were nearly twice as likely to have an SSL found.¹⁹ Conventional adenomas, by contrast, are more common in men and become sharply more common after 50. Having a body mass index of 25 or above was also linked to higher SSL detection in that study.

The age pattern is worth noting because it has implications for screening. Colorectal cancer screening programs were designed around the adenoma-to-carcinoma sequence, which peaks in older adults. The serrated pathway, seeded by SSLs that appear at younger ages, may not be as well captured by screening strategies that begin at 45 or 50. This is an area of active debate among gastroenterologists, and changes to screening recommendations may follow as the data on serrated-pathway cancers mature.

What Patients Understand About Their Polyps

Most people who have polyps removed during colonoscopy leave with a surprisingly poor understanding of what was found. In one study, only about 29% of patients with advanced polyps correctly identified their polyp as precancerous. Nearly 39% believed it was not precancerous, and the rest either did not know or did not answer.²⁰ That gap between clinical reality and patient understanding can lead to missed follow-up appointments and lapsed surveillance, which is exactly the scenario where a sessile serrated lesion gets the time it needs to progress.

If you have had a sessile polyp removed, the pathology report is the document that matters. It will specify the polyp subtype, whether dysplasia was present, the polyp size, and location. Those four details determine your surveillance interval and, more broadly, how seriously to take the finding. A 3 mm hyperplastic polyp in the rectum is a non-event. A 15 mm sessile serrated lesion with dysplasia in the right colon is a finding that demands close follow-up. Asking your gastroenterologist to walk through the pathology report in plain language is one of the highest-value conversations you can have after a colonoscopy.